Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Preclinical Vaccine Efficacy Report and Data Package

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This subcontract, titled Preclinical Vaccine Efficacy Report and Data Package, is issued by the NIH NCI under the Department of Health and Human Services. The primary objective is the compilation of a final technical report that summarizes critical data regarding vector design, production, and validation. This comprehensive documentation must include specific details on gene expression, titers, and preliminary results concerning immunogenicity or efficacy. The project is associated with NAICS code 541690 and is designated for performance in Oxford, UK. Interested parties must adhere to a tight timeline, with the opportunity posted on August 17, 2026, and a response deadline set for August 24, 2026.

General Info

NIH NCI subcontract for preclinical vaccine efficacy reporting and data package in Oxford, UK.

Agency

Department Of Health And Human Services → NIH NciView Agency

NAICS

541690 - Other Scientific and Technical Consulting ServicesView NAICS

Place of Performance

Oxford, GB-OXF, OX3 7DQ, GBR

Set-Aside

NONE

Documents

This scope was carved out of 75N98026Q00996.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Sole Source - Production of ChAdOx-1 and MVA expressing mouse gp70

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → NIH Nci
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Health And Human Services → NIH Nci
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Compile a final technical report summarizing vector design, production, and validation data, including gene expression, titers, and preliminary immunogenicity or efficacy results.

Similar Contracts

Same NAICS industry code

More opportunities from Department Of Health And Human Services → NIH Nci

Same awarding agency

NAICS: 54171
Federal
NATIONAL CANCER INSTITUTE (NCI) SMALL BUSINESS INNOVATION RESEARCH (SBIR) INNOVATIVE CONCEPT PHASE I AWARD PROGRAM
Solicitation # 75N98026R00109
The National Cancer Institute (NCI) is soliciting Phase I Small Business Innovation Research (SBIR) proposals under the Innovative Concept Award Program to advance research and development in therapeutic or preventative technologies, and devices, diagnostic tools, or digital health solutions for pediatric cancers and rare cancers, particularly those with a 5-year survival rate below 50%. This solicitation, numbered 75N98026R00109, is a total small business set-aside under FAR 19.5 with a NAICS code of 54171 and is open exclusively to small business concerns registered in the System for Award Management (SAM) and the SBA Company Registry, with a valid Unique Entity Identifier. Proposals must demonstrate scientific merit without requiring preliminary data, but must clearly articulate an unmet clinical need, the targeted cancer type, a viable development path, and a plan to generate initial proof-of-concept data through well-reasoned experiments. The base R&D budget is $300,000, with an optional additional $6,500 available for technical and business assistance, resulting in a potential contract value of up to $306,500. Amendments to the original solicitation have removed all requirements related to the Data Management and Sharing Plan in Sections 5.9, 6.1, and 8.5, while all other terms, conditions, and submission deadlines remain unchanged. The proposal deadline is September 21, 2026, at 5:00 p.m. Eastern Daylight Time, and submissions must be made electronically via the eCPS portal as a three-part package: a single PDF Technical Proposal including the required form and NIH biosketches, a completed Human Subjects and Clinical Trials Information Form (even if no human subjects are involved), and a single PDF Business Proposal with pricing details. Evaluation will assess technical acceptability, scientific rationale, and security risk as pass/fail gates, followed by a second review by NCI program staff. Contract administration requires electronic funds transfer for payment, mandatory SAM registration as a prerequisite for payment, and compliance with Section 508 for electronic reporting. Non-exempt human subjects research is prohibited, and all contractors must comply with human subjects protection regulations as outlined in 45 CFR part 46, maintain an active Federal-wide Assurance, and adhere to ethics, equal opportunity, E-Verify, and patent infringement reporting requirements. All awards are contingent on funding availability

POSTED

8 days ago

DEADLINE

in about 1 month
View Details